Special Issue

Global Management of Sarcoma Data: Is Real-Time Predictive Analytics on the Horizon?

Message from the Guest Editor

Sarcomas belong to the rare diseases, and its treatment is highly complex and transdisciplinary. The development of novel therapies has been stagnating over years. Although it is accepted that only the interplay of several disciplines may render successful treatment results in sarcoma patients, data are usually still monodisciplinarily reported, and there is no global approach for longitudinal prospective acquisition of structured data on quality. The successful introduction of the "Sarculator" and "PerSarc" -though still imperfect toolshas demonstrated the urge how clinicians starve for outcome prediction tools to incorporate into their strategic treatment decisions. Whereas real-time outcome prediction for sarcoma patients is the defined goal, we have to define the approach how to get there on a global level considering all possible aspects. Herewith, we aim for a current global representation of sarcoma registries available within the existing sarcoma networks with detailed overview how they work. Further, we want to consider the novel opportunities of digital transformation and challenges of international data exchange and analytics.

Guest Editor

Prof. Dr. Bruno Fuchs

Sarcoma Service & IPU, Faculty of Health Science & Medicine, University of Lucerne, CH-6004 Luzern, Switzerland

Deadline for manuscript submissions

closed (30 November 2023)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/115721

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, LISA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

